TC BioPharm (TCBP), a clinical-stage biotechnology firm, has firmly dismissed a baseless claim spread on social media earlier this week. The allegation inaccurately suggested that the company is at risk of being delisted from the Nasdaq stock exchange. The erroneous rumor, which has since been removed, claimed that TC BioPharm had filed an 8-K Notice to "Delist" from Nasdaq and was planning to move its trading activities to another platform.
The company has reaffirmed that there is no truth to this allegation, emphasizing that it remains fully compliant with all Nasdaq listing requirements. TC BioPharm is considering taking measures to protect itself from such unfounded attacks, which appear to be attempts to negatively influence market conditions.
